Literature DB >> 19167828

Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts.

Zhi Zhang1, Tania M Garron, Xiao-Jian Li, Yan Liu, Xiong Zhang, Ye-Yang Li, Wei-Shi Xu.   

Abstract

Decorin was reported to bind transforming growth factor-beta (TGF-beta(1)) and neutralise some of its activity as a key regulator of wound contraction and hypertrophic scar formation. In this study, we investigated whether recombinant human decorin affected TGF-beta(1)-induced fibroblast contractile activity, by using fibroblast-populated collagen lattice with decorin added to the collagen gel. Hypertrophic scar fibroblasts showed greater basal contraction of collagen gels than normal fibroblasts, and the addition of TGF-beta(1) significantly enhanced this. Decorin inhibited both the basal and TGF-beta(1)-enhanced contraction of collagen gel by both normal and hypertrophic scar fibroblasts. Decorin also inhibited TGF-beta(1)-induced alpha-smooth muscle actin (alpha-SMA), plasminogen activator inhibitor-1 (PAI-1) protein and mRNA expressions in normal and hypertrophic scar fibroblasts. These results suggest that decorin may have therapeutic potential for excessive skin contraction as observed in hypertrophic scarring.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167828     DOI: 10.1016/j.burns.2008.08.021

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  33 in total

Review 1.  Prevention of peritoneal adhesions: a promising role for gene therapy.

Authors:  Hussein M Atta
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

2.  The role of osteopontin and osteopontin aptamer (OPN-R3) in fibroblast activity.

Authors:  Cedric Hunter; Jennifer Bond; Paul C Kuo; Maria Angelica Selim; Howard Levinson
Journal:  J Surg Res       Date:  2011-08-27       Impact factor: 2.192

Review 3.  Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.

Authors:  Gerd G Gauglitz; Hans C Korting; Tatiana Pavicic; Thomas Ruzicka; Marc G Jeschke
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

4.  Abnormal scar identification with spherical-nucleic-acid technology.

Authors:  David C Yeo; Christian Wiraja; Amy S Paller; Chad A Mirkin; Chenjie Xu
Journal:  Nat Biomed Eng       Date:  2018-04-13       Impact factor: 25.671

Review 5.  New molecular medicine-based scar management strategies.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-01-15       Impact factor: 2.744

Review 6.  The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring.

Authors:  Richard L Chalmers
Journal:  Int Wound J       Date:  2011-03-30       Impact factor: 3.315

7.  siRNA-targeting transforming growth factor-β type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue.

Authors:  Yi-Wen Wang; Nien-Hsien Liou; Juin-Hong Cherng; Shu-Jen Chang; Kuo-Hsing Ma; Earl Fu; Jiang-Chuan Liu; Niann-Tzyy Dai
Journal:  J Invest Dermatol       Date:  2014-02-13       Impact factor: 8.551

8.  Deficiency of biglycan causes cardiac fibroblasts to differentiate into a myofibroblast phenotype.

Authors:  Ariane Melchior-Becker; Guang Dai; Zhaoping Ding; Liliana Schäfer; Jürgen Schrader; Marian F Young; Jens W Fischer
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

9.  Integral role of platelet-derived growth factor in mediating transforming growth factor-β1-dependent mesenchymal stem cell stiffening.

Authors:  Deepraj Ghosh; Loukia Lili; Daniel J McGrail; Lilya V Matyunina; John F McDonald; Michelle R Dawson
Journal:  Stem Cells Dev       Date:  2013-11-08       Impact factor: 3.272

10.  Decorin-containing collagen hydrogels as dimensionally stable scaffolds to study the effects of compressive mechanical loading on angiogenesis.

Authors:  Marissa A Ruehle; Laxminarayanan Krishnan; Steven A LaBelle; Nick J Willett; Jeffrey A Weiss; Robert E Guldberg
Journal:  MRS Commun       Date:  2017-07-20       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.